​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet (PODD) stock forecast, based on 45 Wall Street analysts, predicts a 12-month average price target of $386.43, with a high of $432.00 and a low of $301.00. This represents a 31.34% increase from the last price of $294.21.

$150 $210 $270 $330 $390 $450 High: $432 Avg: $386.43 Low: $301 Last Closed Price: $294.21

PODD Stock Rating

Insulet stock's rating consensus is Buy, based on 45 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (68.89%), 12 Hold (26.67%), 2 Sell (4.44%), and 0 Strong Sell (0.00%).

Buy
Total 45 2 12 31 0 Strong Sell Sell Hold Buy Strong Buy

PODD Price Target Upside V Benchmarks

TypeNameUpside
StockInsulet31.34%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks19.58%

Price Target Trends

1M3M12M
# Anlaysts51011
Avg Price Target$400.80$383.90$378.27
Last Closing Price$294.21$294.21$294.21
Upside/Downside36.23%30.49%28.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 255182--25
Nov, 255173--25
Oct, 255163--24
Sep, 255163--24
Aug, 256153--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 24, 2025Canaccord Genuity$432.00$331.1730.45%46.83%
Nov 21, 2025Richard NewitterTruist Financial$412.00$325.0026.77%40.04%
Nov 21, 2025Shagun SinghRBC Capital$380.00$324.2017.21%29.16%
Nov 21, 2025BTIG$380.00$312.8921.45%29.16%
Nov 19, 2025UBS$400.00$333.4719.95%35.96%
Nov 06, 2025Matthew TaylorJefferies$400.00$323.4023.69%35.96%
Nov 06, 2025Marie ThibaultBTIG$370.00$323.4014.41%25.76%
Nov 05, 2025Matt MiksicBarclays$301.00$320.27-6.02%2.31%
Oct 10, 2025RBC Capital$365.00$318.0014.78%24.06%
Sep 29, 2025Canaccord Genuity$399.00$318.0025.47%35.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 04, 2025Cowen & Co.BuyBuyhold
Nov 24, 2025Canaccord GenuityBuyBuyhold
Nov 21, 2025RBC CapitalOutperformOutperformhold
Nov 19, 2025UBSBuyBuyupgrade
Nov 06, 2025JefferiesBuyBuyhold
Nov 06, 2025BTIGBuyBuyhold
Oct 10, 2025RBC CapitalOutperformOutperformhold
Aug 07, 2025Morgan StanleyOverweightOverweighthold
Aug 07, 2025JefferiesBuyBuyhold
Jul 08, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.11$0.25$0.07$2.96$5.97----
Avg Forecast$0.32$0.13$0.42$1.99$3.21$3.93$4.95$5.96$7.30
High Forecast$0.33$0.13$0.43$2.08$3.36$4.30$5.68$6.79$7.55
Low Forecast$0.32$0.13$0.41$1.86$3.11$3.71$3.58$4.76$7.08
Surprise %-65.63%92.31%-83.33%48.74%85.98%----

Revenue Forecast

$500M $1B $2B $3B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$904.40M$1.10B$1.31B$1.70B$2.07B----
Avg Forecast$891.32M$1.09B$1.27B$1.65B$2.06B$2.43B$2.86B$3.32B$3.75B
High Forecast$909.66M$1.11B$1.30B$1.69B$2.11B$2.49B$2.86B$3.35B$3.85B
Low Forecast$876.78M$1.07B$1.24B$1.64B$2.05B$2.40B$2.85B$3.28B$3.67B
Surprise %1.47%0.66%2.88%2.96%0.71%----

Net Income Forecast

$-150M $0 $150M $300M $450M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.80M$16.80M$4.60M$206.30M$418.30M----
Avg Forecast$23.92M$4.65M$-70.49M$206.30M$238.15M$289.34M$368.31M$434.07M$537.52M
High Forecast$24.56M$17.25M$-30.76M$322.59M$247.32M$316.29M$418.31M$499.77M$555.71M
Low Forecast$23.41M$-7.94M$-110.23M$90.01M$228.97M$273.53M$263.30M$350.38M$521.49M
Surprise %-71.57%261.00%-106.53%-75.65%----

PODD Forecast FAQ

Is Insulet stock a buy?

Insulet stock has a consensus rating of Buy, based on 45 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 12 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Insulet is a favorable investment for most analysts.

What is Insulet's price target?

Insulet's price target, set by 45 Wall Street analysts, averages $386.43 over the next 12 months. The price target range spans from $301 at the low end to $432 at the high end, suggesting a potential 31.34% change from the previous closing price of $294.21.

How does Insulet stock forecast compare to its benchmarks?

Insulet's stock forecast shows a 31.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (19.58%).

What is the breakdown of analyst ratings for Insulet over the past three months?

  • December 2025: 20.00% Strong Buy, 72.00% Buy, 8.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 20.00% Strong Buy, 68.00% Buy, 12.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 20.83% Strong Buy, 66.67% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Insulet’s EPS forecast?

Insulet's average annual EPS forecast for its fiscal year ending in December 2025 is $3.93, marking a -34.17% decrease from the reported $5.97 in 2024. Estimates for the following years are $4.95 in 2026, $5.96 in 2027, and $7.3 in 2028.

What is Insulet’s revenue forecast?

Insulet's average annual revenue forecast for its fiscal year ending in December 2025 is $2.43B, reflecting a 17.42% increase from the reported $2.07B in 2024. The forecast for 2026 is $2.86B, followed by $3.32B for 2027, and $3.75B for 2028.

What is Insulet’s net income forecast?

Insulet's net income forecast for the fiscal year ending in December 2025 stands at $289.34M, representing a -30.83% decrease from the reported $418.3M in 2024. Projections indicate $368.31M in 2026, $434.07M in 2027, and $537.52M in 2028.